logo

For the Inventor, By the Inventor

Daejeon, South Korea

Hanall Biopharma Co., Ltd.


USPTO Granted Patents = 27



Trademarks = 2

Forward Citations = 107

Loading Chart...
Loading Chart...

52 inventors (with patents filed for the assignee):

goldMedal Sung Wuk Kim (16 out of 31 patents)

silverMedal Sung Soo Jun (12 out of 17 patents)

bronzeMedal Thierry Guyon (9 out of 14 patents)

4.  Manuel Vega (9 out of 14 patents)

5.  Lila Drittanti (9 out of 15 patents)

6.  Eun Sun Kim (8 out of 166 patents)

7.  Yeon Jung Song (8 out of 10 patents)

8.  Seung Kook Park (8 out of 13 patents)

9.  Jae Kap Jeong (8 out of 12 patents)

10.  Rene Gantier (5 out of 7 patents)

11.  Young Gwan Jo (5 out of 6 patents)

12.  Hyea Kyung Ahn (4 out of 5 patents)

13.  Hae-Young Yong (4 out of 4 patents)

14.  Dongok Shin (4 out of 4 patents)

15.  Hyae Gyeong Cheon (4 out of 9 patents)


27 patents:

1. 11926669 - Anti-FcRn antibody or antigen binding fragment thereof with improved stability (2024-03-12),
2. 11613578 - Antibody binding to FCRN for treating autoimmune diseases (2023-03-28),
3. 10544226 - Antibody binding to FcRn for treating autoimmune diseases (2020-01-28),
4. 10336825 - Antibody binding to FcRn for treating autoimmune diseases (2019-07-02),
5. 10280207 - FcRn-specific human antibody and composition for treatment of autoimmune diseases (2019-05-07),
6. 9655916 - Compositions for external application, containing adenosylcobalamin for improvement of skin diseases (2017-05-23),
7. 9580490 - Uses of modified human tumor necrosis factor receptor-1 polypeptide (2017-02-28),
8. 9133110 - Biguanide derivative, preparation method thereof, and pharmaceutical composition containing same as an active ingredient (2015-09-15),
9. 9068019 - Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same (2015-06-30),
10. 8895500 - Modified human tumor necrosis factor receptor-I polypeptide or fragment thereof, and method for preparing same (2014-11-25),
11. 8754037 - Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same (2014-06-17),
12. 8722674 - 1,3,5-triazine-2,4,6-triamine compound or pharmaceutical acceptable salt thereof, and pharmaceutical composition comprising the same (2014-05-13),
13. 8648111 - N1-2-thiophene-2-ylethyl-N2-substituted biguanide derivate, preparation method thereof, and pharmaceutical composition containing the same as active ingredients (2014-02-11),
14. 8642647 - N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative, preparation method thereof, and pharmaceutical composition containing same (2014-02-04),
15. 8642083 - Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors (2014-02-04),
HANALL BIOPHARMA CO., LTD. is a reputable biopharmaceutical company engaged in research, development, manufacturing, and marketing of innovative therapeutic products. With a focus on improving public health and enhancing the quality of life, HANALL aims to provide effective, safe, and affordable pharmaceutical solutions. The company's diverse portfolio includes a wide range of pharmaceuticals spanning various therapeutic areas such as oncology, cardiovascular, neurological disorders, metabolic diseases, and more. HANALL's commitment to scientific excellence and clinical research has led to the development of groundbreaking treatments that have positively impacted patients worldwide.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

27 Patents

#31 in Daejeon

#481 in South Korea

#23,270 in the World

...
Daejeon, South Korea

Hanall Biopharma Co., Ltd.

Forward Citations = 107

52 inventors:

goldMedal Sung Wuk Kim (16 out of 31 patents)

silverMedal Sung Soo Jun (12 out of 17 patents)

bronzeMedal Thierry Guyon (9 out of 14 patents)

4.  Manuel Vega (9 out of 14 patents)

5.  Lila Drittanti (9 out of 15 patents)

Please report any incorrect information to support@idiyas.com
Loading…